Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
|Articles|April 28, 2023
POLL: What Topics Do You Want to See Us Cover at RAD?
Author(s)Dermatology Times Staff
Let us know what content you want to see from RAD.
Advertisement
The 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference begins tomorrow in Washington, DC. As the editors of Dermatology Times® prepare to bring you the latest content from the meeting, what topics are you most interested in?
What topics do you want to see us cover at RAD?
Keep up to date with the latest in coverage from the conference and subscribe to
Advertisement
Related to this article
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5